

# Mark N Adams

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8093995/publications.pdf>

Version: 2024-02-01

40  
papers

1,369  
citations

394421

19  
h-index

434195

31  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure, function and pathophysiology of protease activated receptors. , 2011, 130, 248-282.		315
2	Nucleophosmin: from structure and function to disease development. BMC Molecular Biology, 2016, 17, 19.	3.0	189
3	Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising. Frontiers in Oncology, 2014, 4, 86.	2.8	100
4	Proteolysis-induced N-terminal Ectodomain Shedding of the Integral Membrane Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Is Accompanied by Tyrosine Phosphorylation of Its C-terminal Domain and Recruitment of Src and PKC $\delta$ . Journal of Biological Chemistry, 2010, 285, 26162-26173.	3.4	62
5	Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1071-1084.	1.1	59
6	Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene, 2016, 35, 468-478.	5.9	45
7	The Role of Palmitoylation in Signalling, Cellular Trafficking and Plasma Membrane Localization of Protease-Activated Receptor-2. PLoS ONE, 2011, 6, e28018.	2.5	41
8	Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. Nature Communications, 2019, 10, 5501.	12.8	40
9	CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of $\beta$ -catenin and E-cadherin. Oncogene, 2020, 39, 219-233.	5.9	39
10	Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological Chemistry, 2008, 389, 653-668.	2.5	38
11	hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway. Nucleic Acids Research, 2015, 43, 8817-8829.	14.5	37
12	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. British Journal of Cancer, 2016, 114, 417-426.	6.4	35
13	EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. Oncogene, 2015, 34, 1375-1383.	5.9	33
14	hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress. Scientific Reports, 2016, 6, 27446.	3.3	31
15	Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273.	3.8	28
16	A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution. Nucleic Acids Research, 2016, 44, 7963-7973.	14.5	26
17	Human single-stranded DNA binding protein 1 (hSSB1, OBFC2B), a critical component of the DNA damage response. Seminars in Cell and Developmental Biology, 2019, 86, 121-128.	5.0	26
18	Targeting NF- $\kappa$ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 2019, 135, 217-227.	2.0	25

#	ARTICLE	IF	CITATIONS
19	Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. <i>Cell Death and Disease</i> , 2016, 7, e2469-e2469.	6.3	22
20	Evaluation of antibodies directed against human protease-activated receptor-2. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 861-873.	3.0	20
21	Potent Small Agonists of Protease Activated Receptor 2. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 105-110.	2.8	16
22	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18605.	3.3	16
23	A data-driven structural model of hSSB1 (NABP2/OBFC2B) self-oligomerization. <i>Nucleic Acids Research</i> , 2017, 45, 8609-8620.	14.5	14
24	FGFR2b activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer. <i>Journal of Cell Science</i> , 2018, 131, .	2.0	14
25	Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases. <i>Biological Chemistry</i> , 2014, 395, 977-990.	2.5	13
26	Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2020, 123, 591-603.	6.4	13
27	Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy. <i>Communications Biology</i> , 2021, 4, 638.	4.4	12
28	DNA repair pathways and their therapeutic potential in lung cancer. <i>Lung Cancer Management</i> , 2014, 3, 159-173.	1.5	10
29	Mapping transmembrane residues of proteinase activated receptor 2 (PAR 2 ) that influence ligand-modulated calcium signaling. <i>Pharmacological Research</i> , 2017, 117, 328-342.	7.1	8
30	COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks. <i>Communications Biology</i> , 2021, 4, 484.	4.4	8
31	24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S65.	1.1	5
32	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 4651.	3.7	5
33	3D Breast Tumor Models for Radiobiology Applications. <i>Cancers</i> , 2021, 13, 5714.	3.7	5
34	17P Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, S63.	1.1	4
35	Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. <i>Oncogenesis</i> , 2021, 10, 41.	4.9	3
36	16P The overexpression of SASH1 stimulates cell death in lung cancer cells. <i>Journal of Thoracic Oncology</i> , 2016, 11, S62-S63.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Targeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients. <i>Annals of Oncology</i> , 2019, 30, v101.	1.2	2
38	MA 03.11 Targeting CDCA3 Enhances Sensitivity to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1810-S1811.	1.1	0
39	P1.01-01 Clinical Relevance of Targeting Proteins Required for Mitotic Progression to Improve Chemotherapy Response in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S354.	1.1	0
40	P1.03-05 COMMD4 in Lung Cancer: Towards a New Therapeutic Target and Diagnostic Biomarker. <i>Journal of Thoracic Oncology</i> , 2019, 14, S419.	1.1	0